Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Insights
  2. Events
  3. About
  4. Contact Us
MAIN/search
MAIN/Insights
Insights/
Our Latest Whitepapers

Get the latest insights on our life sciences, healthcare, and medical technology solutions in Asia Pacific. 

Learn More
Blogs, Case Studies & Podcasts

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

Discover Insights

IQVIA APAC Insight

"A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the Asia Pacific healthcare market.

Read The Latest Issue
MAIN/Events
Events/
Upcoming Events & Webinars

View our upcoming events and webinars.

Explore The Latest
On-Demand Webinars

Visit our library of on-demand webinars.

Discover Insights

Featured Event

"Unlocking the Future of Consumer Health: A Special Focus on Senior Consumers

Learn More
MAIN/About
About/
Newsroom

Read the latest updates and press releases.

Learn More
Career Opportunities

Improving human health requires innovative thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

Search Jobs

APAC FOOTPRINT

"Explore our Asia Pacific locations.

Learn more
MAIN/Contact Us
Contact Us/
WHITE PAPER
Catalyzing Sustainable Funding for Rare Diseases
Aug 07, 2023
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

400 million patients worldwide are affected by over 7000 different types of rare diseases. More countries are now recognising the need for patients with rare diseases to have access to care by exploring alternative funding methods for rare diseases.

In continuation to our series of Innovative Funding Trends And Models, Roche and IQVIA has jointly published a new white paper that aims to continuously enrich the discussion on the improvement of the rare disease funding environment. It will describe the challenges with rare disease access and funding as well as provide a deep dive into the significant progress in the rare disease funding and access landscape shown in twelve Lower Middle-Income Countries (LMICs). Finally, the paper also provides suggestions on three strategic imperatives for countries to improve their rare disease environment.

Contact Us